Business
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery
About this update from Sana Biotechnology, Inc.
[{"type":"text","content":"Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells\nSEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. Late-breaking poster details: Title:Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cellsSession Title:Late-Breaking Research: Experimental and Molecular Therapeutics 3Session Date:Wednesday, April 19, 2023Session Time:9:00 a.m. - 12:30 p.m. ETLocation:Poster Section 35Abstract Number:LB311 Poster details: Title:Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomesSession Category:Experimental and Molecular TherapeuticsSession Title:Gene and Vector-based TherapySession Date:Monday, April 17, 2023Session Time:1:30 p.m. - 5:00 p.m. ETLocation:Poster Section 16Abstract Number:2734 Title:Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosomeSession Category:Experimental and Molecular TherapeuticsSession Title:Gene and Vector-based TherapySession Date:Monday, April 17, 2023Session Time:1:30 p.m. - 5:00 p.m. ETLocation:Poster Section 16Abstract Number:2735 Title:Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challengeSession Category:ImmunologySession Title:CAR T-cell Therapy 2Session Date:Tuesday, April 18, 2023Session Time:9:00 a.m. - 12:30 p.m. ETLocation:Poster Section 23Abstract Number:4091 Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET. About Sana BiotechnologySa...